Silence Therapeutics – based in Hammersmith, West London – is to be acquired by Germany’s Merck KGaA in an all-cash deal worth $1.3bn, struck after the biotech’s lead siRNA candidate posted an 88% response rate in a mid-stage blood cancer trial.
Darmstadt-based Merck will pay $20 per American depositary share, with each ADS representing three ordinary shares of Silence. The prize is divesiran, a short interfering RNA candidate designed to treat polycythemia vera, a rare blood cancer characterised by the excessive production of red blood cells. Divesiran silences the production of a protein, TMPRSS6, found in liver cells, redirecting iron delivery away from the bone marrow and slowing the production of red blood cells. In August, Silence reported that 88% of patients on divesiran in a phase 2 study had met the response criteria between Weeks 18 and 36 – 93.8% of those dosed every six weeks and 81.3% of the 12-week cohort – data the company is using as a springboard into phase 3.
Silence goes into that trial as a follower to Takeda and Protagonist’s Mimrylo, approved by the FDA for polycythemia vera in August, and its hopes rest on dosing: Mimrylo was given as a weekly, self-administered injection in phase 3, while Silence plans to administer divesiran every 12 weeks. The rest of the pipeline includes zerlasiran, an siRNA therapy aimed at atherosclerotic cardiovascular disease, and SLN312, which targets ANGPTL3 as a route to treating dyslipidemia. For Merck’s new chief executive Kai Beckmann, who took over in May, the deal follows an $11bn-plus purchase of Bio-Techne and continues a stated commitment to broaden the group’s M&A scope.
For West London, this is the far end of the scale-up journey. Silence runs its UK headquarters from Hammersmith Grove, in the London Borough of Hammersmith and Fulham, and a trade sale on this scale is the kind of outcome that makes the borough’s life sciences base globally visible. LWIN’s interest is less in the exit itself than in what follows it. We hope the research and the people stay in West London once the deal completes.
“This transaction follows potentially best-in-class phase 2 polycythemia vera data for divesiran and reflects the important progress we have made advancing our differentiated siRNA pipeline.”
Iain Ross, interim principal executive officer and chairperson of Silence Therapeutics’ board, quoted in Fierce Biotech
Reported by James Waldron for Fierce Biotech, 19 October 2026. Read the full article on Fierce Biotech →